Cargando…

Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

OBJECTIVES: To evaluate the impact of smoking history on the clinical benefit of immunotherapy in patients with non-small cell lung cancer (NSCLC). METHODS: Twenty-three randomized clinical trials and seven real-world studies were included in this meta-analysis. Hazard ratios (HRs) and 95% confidenc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Wenhua, Jiang, Wei, Wang, Huilin, He, Jianbo, Su, Cuiyun, Yu, Qitao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419340/ https://www.ncbi.nlm.nih.gov/pubmed/34497760 http://dx.doi.org/10.3389/fonc.2021.703143

Ejemplares similares

The Effect of PD-1 Inhibitor Combined with Chemotherapy on the Level of Peripheral Blood T Lymphocytes among Patients with Non-Small-Cell Lung Cancer and Its Relationship with Prognosis
por: Zhao, Yun, et al.
Publicado: (2022)

Case Report: The effective treatment of patients in advanced no-small cell lung cancer patients with EGFR G719X/S768I/L861Q and acquired MET amplification: A case series and literature review
por: Zhao, Yun, et al.
Publicado: (2023)

PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study
por: Chen, Shubin, et al.
Publicado: (2022)

Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis
por: Wang, He, et al.
Publicado: (2022)

Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis
por: Wang, Min, et al.
Publicado: (2015)

Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis
por: Ni, Yunfeng, et al.
Publicado: (2023)

STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review
por: Su, Cuiyun, et al.
Publicado: (2020)

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
por: Peng, Yurong, et al.
Publicado: (2023)

Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis
por: Liang, Jiali, et al.
Publicado: (2022)

Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis
por: Alifu, Muyesar, et al.
Publicado: (2023)

Corrigendum: Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
por: Peng, Yurong, et al.
Publicado: (2023)

Distinct EGFR Mutation Pattern in Patients With Non-Small Cell Lung Cancer in Xuanwei Region of China: A Systematic Review and Meta-Analysis
por: Lv, Li, et al.
Publicado: (2020)

Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases
por: Fang, Yujia, et al.
Publicado: (2022)

Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Zeng, Yuan, et al.
Publicado: (2016)

The Association between Pretreatment anemia and Overall Survival in Advanced Non-small Cell lung Cancer: A Retrospective Cohort Study Using Propensity Score Matching
por: Huang, Yucong, et al.
Publicado: (2022)

Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
por: Wang, Yunzhen, et al.
Publicado: (2023)

Impact of Sex and Smoking on the Efficacy of EGFR-TKIs in Terms of Overall Survival in Non-small-Cell Lung Cancer: A Meta-Analysis
por: Xiao, Jian, et al.
Publicado: (2020)

Predictive value of tumor genetic alteration profiling for chemotherapy and EGFR-TKI treatment in advanced NSCLC
por: Jiang, Wei, et al.
Publicado: (2020)

Immunotherapy in non-small cell lung cancer: Past, present, and future directions
por: Punekar, Salman R., et al.
Publicado: (2022)

Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review
por: Li, Lingling, et al.
Publicado: (2020)

Adjuvant immunotherapy in early-stage resectable non–small cell lung cancer: A new milestone
por: Tang, Wen-Fang, et al.
Publicado: (2023)

Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Liu, Ying, et al.
Publicado: (2021)

Toxicities of Immunotherapy for Small Cell Lung Cancer
por: Fu, Yang, et al.
Publicado: (2021)

Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine
por: Tabchi, Samer, et al.
Publicado: (2017)

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
por: Seegobin, Karan, et al.
Publicado: (2021)

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
por: Wu, Xinyu, et al.
Publicado: (2023)

Predicting response to immunotherapy in non-small cell lung cancer- from bench to bedside
por: Montoya, Chris, et al.
Publicado: (2023)

The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Xu, Yangyang, et al.
Publicado: (2021)

Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
por: Zhang, Xiaofei, et al.
Publicado: (2023)

Metabolomics profiling in prediction of chemo-immunotherapy efficiency in advanced non-small cell lung cancer
por: Mei, Lihong, et al.
Publicado: (2023)

Combining stereotactic body radiotherapy with immunotherapy in stage IV non-small cell lung cancer
por: Liu, Xiaoli, et al.
Publicado: (2023)

Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
por: Fang, Min, et al.
Publicado: (2023)

Treatment beyond progression in non-small cell lung cancer: A systematic review and meta-analysis
por: Kuo, Wei-Ke, et al.
Publicado: (2022)

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review
por: Garon, Edward B., et al.
Publicado: (2023)

The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer
por: Wong, Annick
Publicado: (2017)

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Wang, Xue, et al.
Publicado: (2021)

Expression of Microtubule-Associated Proteins in Relation to Prognosis and Efficacy of Immunotherapy in Non-Small Cell Lung Cancer
por: Luo, Jieyan, et al.
Publicado: (2021)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
por: Martin, Claudio, et al.
Publicado: (2022)

Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases
por: Liu, Hao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p8bgp90quarn796rr7re0qu6pp